Adjuvant Radiotherapy Significantly Reduces Recurrence Risk in Atypical Meningioma Patients

A landmark international phase 3 randomized controlled trial, ROAM/EORTC-1308, has provided a definitive answer to a long-standing neuro-oncology dilemma. The study demonstrated that radiotherapy administered after the complete surgical removal of an atypical meningioma significantly lowers the likelihood of tumor recurrence. This finding is expected to reshape standard care globally for patients with this challenging brain tumor.